<p>F M Investments LLC 在最近向美国证券交易委员会提交的 13F 文件中表示，在第三季度将其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的股份减少了 10.0%。该机构投资者在季度内出售了 4,731 股后，持有该制药公司 42,463 股股票。Vertex Pharmaceuticals 占 F M Investments LLC 投资组合的 0.7%，使其成为该投资组合中第 27 大持仓。截至其最近向美国证券交易委员会提交的文件，F M Investments LLC 在 Vertex Pharmaceuticals 的持股价值为 19,749,000 美元。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
<ul>
<li>生物科技股票突破：IBB 关注 Amgen 和 Vertex 的阻力位</li>
</ul>
<p>其他机构投资者和对冲基金最近也对该公司的持仓进行了调整。Northwest Investment Counselors LLC 在第三季度购买了价值 25,000 美元的 Vertex Pharmaceuticals 新股份。Highline Wealth Partners LLC 在第三季度购买了价值 27,000 美元的 Vertex Pharmaceuticals 新股份。GHP Investment Advisors Inc. 在第二季度购买了价值 29,000 美元的 Vertex Pharmaceuticals 新股份。Stephens Consulting LLC 在第二季度购买了价值 31,000 美元的 Vertex Pharmaceuticals 新股份。最后，Founders Capital Management 在第二季度将其在 Vertex Pharmaceuticals 的持仓增加了 50.0%。Founders Capital Management 现在拥有 75 股该制药公司的股票，价值 35,000 美元，此前在此期间又购买了 25 股。对冲基金和其他机构投资者持有该公司 90.96% 的股份。</p>
<h2>华尔街分析师观点</h2>
<p>一些股票研究分析师最近对 VRTX 股票发表了看法。HC Wainwright 在 10 月 21 日的研究报告中重申了 &#34;买入&#34; 评级，并设定了 600.00 美元的目标价。Guggenheim 将 Vertex Pharmaceuticals 的目标价从 450.00 美元上调至 558.00 美元，并在 8 月 2 日的研究报告中给予该公司 &#34;买入&#34; 评级。TD Cowen 将 Vertex Pharmaceuticals 的目标价从 450.00 美元上调至 500.00 美元，并在 7 月 23 日的研究报告中给予该公司 &#34;买入&#34; 评级。摩根士丹利在 10 月 1 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 462.00 美元上调至 474.00 美元，并给予该公司 &#34;同等权重&#34; 评级。最后，Scotiabank 在 10 月 16 日的研究报告中开始覆盖 Vertex Pharmaceuticals 的股票。他们设定了 &#34;行业表现&#34; 评级和 480.00 美元的目标价。三位研究分析师对该股票给予了卖出评级，十位给予了持有评级，十七位给予了买入评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 目前的共识评级为 &#34;持有&#34;，共识目标价为 492.50 美元。</p>
<ul>
<li>生物科技行业会从滞后者转变为领导者吗？</li>
</ul>
<p><strong>查看我们最新的 VRTX 股票分析</strong></p>
<h2>Vertex Pharmaceuticals 股票表现</h2>
<p>VRTX 周五开盘价为 471.12 美元。该公司的市值为 1216 亿美元，市盈率为 -232.08，贝塔值为 0.39。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 341.90 美元，1 年最高价为 510.64 美元。该公司的 50 日简单移动平均线为 474.53 美元，200 日简单移动平均线为 464.46 美元。该公司的债务与股本比率为 0.02，流动比率为 2.52，速动比率为 2.26。</p>
<ul>
<li>生物科技行业接近突破：第二季度会表现优于市场吗？</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近在 8 月 1 日发布了季度财报。该制药公司报告本季度每股收益为（12.83 美元），低于分析师的共识预期（12.54 美元）0.29 美元。该公司本季度的收入为 26.5 亿美元，而共识预期为 26.6 亿美元。Vertex Pharmaceuticals 的股本回报率为 -2.45%，净利润率为 -4.74%。该公司本季度的收入较去年同期增长了 6.1%。在去年同期，该公司每股收益为 3.53 美元。股票分析师预测，Vertex Pharmaceuticals Incorporated 本财年将发布 -2.04 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在 Vertex Pharmaceuticals 的其他新闻中，董事长 Jeffrey M. Leiden 于 8 月 30 日星期五出售了 3,784 股公司股票。股票的平均售价为 499.00 美元，总价值为 1,888,216.00 美元。交易完成后，董事长现在直接持有 9,994 股公司股票，价值 4,987,006 美元。这代表其持股比例下降了 0.00%。该交易已在向美国证券交易委员会（SEC）提交的文件中披露，相关文件可通过此链接获取。相关消息中，首席营销官 Carmen Bozic 于 8 月 7 日星期三出售了 2,280 股公司股票。股票的平均售价为 476.75 美元，总交易额为 1,086,990.00 美元。交易完成后，首席营销官现在持有 23,259 股公司股票，价值约 11,088,728.25 美元。这代表其持股比例下降了 0.00%。该销售已在向证券交易委员会的法律文件中披露，相关文件可通过此链接访问。此外，董事长 Jeffrey M. Leiden 于 8 月 30 日星期五再次出售了 3,784 股公司股票。股票的平均售价为 499.00 美元，总交易额为 1,888,216.00 美元。交易完成后，董事长现在持有 9,994 股公司股票，价值约 4,987,006 美元。这代表其持股比例下降了 0.00%。该销售的披露信息可在此找到。过去三个月内，内部人士共出售了 6,710 股公司股票，价值 3,298,206 美元。目前，内部人士持有公司股票的比例为 0.20%。</p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO，适用于使用 ivacaftor 的患者。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>零售商之战：谁将胜出？</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>HCA Healthcare：暂时的挫折，长期的实力</li>
<li>复利是如何计算的？</li>
<li>MarketBeat 周报 – 10/28 - 11/1</li>
</ul>
<p><strong>想看看其他对 VRTX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<p>→ 我们在 2016 年推荐了 Nvidia，现在我们推荐这个……（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDEzMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDEzMQ"/></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了 &#34;持有&#34; 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>F M Investments LLC 在第三季度减少了对 Vertex Pharmaceuticals (NASDAQ:VRTX) 的持股比例，下降了 10%，目前持有 42,463 股，价值 7,749,000 美元。其他机构投资者也调整了他们的持仓。分析师对该股票的评级意见不一，普遍评级为 “持有”，目标价格为 329.50 美元。Vertex 最近的财报显示每股亏损 0.83 美元，未达到预期，收入为 6.5 亿美元。该股票开盘价为 329.12 美元，市值为 836 亿美元，市盈率为 -232.08</p>

<p>F M Investments LLC lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 10.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,463 shares of the pharmaceutical company's stock after selling 4,731 shares during the quarter. Vertex Pharmaceuticals accounts for 0.7% of F M Investments LLC's investment portfolio, making the stock its 27th biggest position. F M Investments LLC's holdings in Vertex Pharmaceuticals were worth $19,749,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>F M Investments LLC 在最近向美国证券交易委员会提交的 13F 文件中表示，在第三季度将其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的股份减少了 10.0%。该机构投资者在季度内出售了 4,731 股后，持有该制药公司 42,463 股股票。Vertex Pharmaceuticals 占 F M Investments LLC 投资组合的 0.7%，使其成为该投资组合中第 27 大持仓。截至其最近向美国证券交易委员会提交的文件，F M Investments LLC 在 Vertex Pharmaceuticals 的持股价值为 19,749,000 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技股票突破：IBB 关注 Amgen 和 Vertex 的阻力位</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently made changes to their positions in the company. Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $27,000. GHP Investment Advisors Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $29,000. Stephens Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $31,000. Finally, Founders Capital Management raised its position in Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company's stock worth $35,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也对该公司的持仓进行了调整。Northwest Investment Counselors LLC 在第三季度购买了价值 25,000 美元的 Vertex Pharmaceuticals 新股份。Highline Wealth Partners LLC 在第三季度购买了价值 27,000 美元的 Vertex Pharmaceuticals 新股份。GHP Investment Advisors Inc. 在第二季度购买了价值 29,000 美元的 Vertex Pharmaceuticals 新股份。Stephens Consulting LLC 在第二季度购买了价值 31,000 美元的 Vertex Pharmaceuticals 新股份。最后，Founders Capital Management 在第二季度将其在 Vertex Pharmaceuticals 的持仓增加了 50.0%。Founders Capital Management 现在拥有 75 股该制药公司的股票，价值 35,000 美元，此前在此期间又购买了 25 股。对冲基金和其他机构投资者持有该公司 90.96% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts have recently weighed in on VRTX shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $600.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, October 21st. Guggenheim lifted their target price on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 2nd. TD Cowen lifted their target price on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, July 23rd. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, October 1st. Finally, Scotiabank assumed coverage on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 16th. They set a &#34;sector perform&#34; rating and a $480.00 price target for the company. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $492.50.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 VRTX 股票发表了看法。HC Wainwright 在 10 月 21 日的研究报告中重申了 &#34;买入&#34; 评级，并设定了 600.00 美元的目标价。Guggenheim 将 Vertex Pharmaceuticals 的目标价从 450.00 美元上调至 558.00 美元，并在 8 月 2 日的研究报告中给予该公司 &#34;买入&#34; 评级。TD Cowen 将 Vertex Pharmaceuticals 的目标价从 450.00 美元上调至 500.00 美元，并在 7 月 23 日的研究报告中给予该公司 &#34;买入&#34; 评级。摩根士丹利在 10 月 1 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 462.00 美元上调至 474.00 美元，并给予该公司 &#34;同等权重&#34; 评级。最后，Scotiabank 在 10 月 16 日的研究报告中开始覆盖 Vertex Pharmaceuticals 的股票。他们设定了 &#34;行业表现&#34; 评级和 480.00 美元的目标价。三位研究分析师对该股票给予了卖出评级，十位给予了持有评级，十七位给予了买入评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 目前的共识评级为 &#34;持有&#34;，共识目标价为 492.50 美元。</p>
</div><ul>
<li>Will the Biotech Sector Shift From Lagger to Leader?</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行业会从滞后者转变为领导者吗？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on VRTX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 VRTX 股票分析</strong></p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表现</h2>
</div><p>VRTX opened at $471.12 on Friday. The firm has a market cap of $121.60 billion, a P/E ratio of -232.08 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64. The company has a 50 day simple moving average of $474.53 and a two-hundred day simple moving average of $464.46. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26.</p>
<div class="lb-trans"><p>VRTX 周五开盘价为 471.12 美元。该公司的市值为 1216 亿美元，市盈率为 -232.08，贝塔值为 0.39。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 341.90 美元，1 年最高价为 510.64 美元。该公司的 50 日简单移动平均线为 474.53 美元，200 日简单移动平均线为 464.46 美元。该公司的债务与股本比率为 0.02，流动比率为 2.52，速动比率为 2.26。</p>
</div><ul>
<li>Biotech Sector Nears Breakout: Will it Outperform in Q2?</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行业接近突破：第二季度会表现优于市场吗？</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts' consensus estimates of ($12.54) by ($0.29). The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business's revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.53 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.04 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近在 8 月 1 日发布了季度财报。该制药公司报告本季度每股收益为（12.83 美元），低于分析师的共识预期（12.54 美元）0.29 美元。该公司本季度的收入为 26.5 亿美元，而共识预期为 26.6 亿美元。Vertex Pharmaceuticals 的股本回报率为 -2.45%，净利润率为 -4.74%。该公司本季度的收入较去年同期增长了 6.1%。在去年同期，该公司每股收益为 3.53 美元。股票分析师预测，Vertex Pharmaceuticals Incorporated 本财年将发布 -2.04 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CMO Carmen Bozic sold 2,280 shares of the company's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the completion of the transaction, the chief marketing officer now owns 23,259 shares in the company, valued at approximately $11,088,728.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares of the company's stock, valued at approximately $4,987,006. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,710 shares of company stock worth $3,298,206 over the last three months. 0.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在 Vertex Pharmaceuticals 的其他新闻中，董事长 Jeffrey M. Leiden 于 8 月 30 日星期五出售了 3,784 股公司股票。股票的平均售价为 499.00 美元，总价值为 1,888,216.00 美元。交易完成后，董事长现在直接持有 9,994 股公司股票，价值 4,987,006 美元。这代表其持股比例下降了 0.00%。该交易已在向美国证券交易委员会（SEC）提交的文件中披露，相关文件可通过此链接获取。相关消息中，首席营销官 Carmen Bozic 于 8 月 7 日星期三出售了 2,280 股公司股票。股票的平均售价为 476.75 美元，总交易额为 1,086,990.00 美元。交易完成后，首席营销官现在持有 23,259 股公司股票，价值约 11,088,728.25 美元。这代表其持股比例下降了 0.00%。该销售已在向证券交易委员会的法律文件中披露，相关文件可通过此链接访问。此外，董事长 Jeffrey M. Leiden 于 8 月 30 日星期五再次出售了 3,784 股公司股票。股票的平均售价为 499.00 美元，总交易额为 1,888,216.00 美元。交易完成后，董事长现在持有 9,994 股公司股票，价值约 4,987,006 美元。这代表其持股比例下降了 0.00%。该销售的披露信息可在此找到。过去三个月内，内部人士共出售了 6,710 股公司股票，价值 3,298,206 美元。目前，内部人士持有公司股票的比例为 0.20%。</p>
</div><h2>Vertex Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO，适用于使用 ivacaftor 的患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Battle of the Retailers: Who Comes Out on Top?</li>
<li>Insider Trading - What You Need to Know</li>
<li>HCA Healthcare: Temporary Setbacks, Long-Term Strength</li>
<li>How is Compound Interest Calculated?</li>
<li>MarketBeat Week in Review – 10/28 - 11/1</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>零售商之战：谁将胜出？</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>HCA Healthcare：暂时的挫折，长期的实力</li>
<li>复利是如何计算的？</li>
<li>MarketBeat 周报 – 10/28 - 11/1</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 VRTX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><p>→ We recommended Nvidia in 2016, now we’re recommending this… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 我们在 2016 年推荐了 Nvidia，现在我们推荐这个……（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDEzMQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10131&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Vertex Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了 &#34;持有&#34; 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

F M Investments LLC 减少了在福泰制药公司（NASDAQ:VRTX）的持股